Indian Pharma Sites See Reduced US FDA Enforcement Actions Amid Expanding Surprise Inspections in FY26

Indian Pharmaceutical Manufacturing Sites See Decline in USFDA Enforcement Actions

In fiscal 2026, Indian pharmaceutical manufacturing sites witnessed a significant decline in US Food and Drug Administration (USFDA) enforcement actions. According to official data, the number of Official Action Indicated (OAI) findings more than halved year-on-year, falling to three in FY26 from seven in FY25. This trend reflects a broader decline in inspection volume, with the USFDA conducting 212 drug facility inspections in 2025, down from 284 in 2024 in India.

The decline in OAI findings is a welcome development for Indian drugmakers, which rely heavily on the US market for a significant portion of their revenues. The US remains the most critical overseas market for Indian drug manufacturers, accounting for around one-third to 40 percent of their revenues, driven largely by generic medicines and complex formulations.

The USFDA's shift towards unannounced foreign inspections appears to be a key factor behind the decline in OAI findings. Unannounced inspections, which were introduced more broadly for foreign drugmakers from May 2025, have altered how facilities are assessed rather than what is assessed. Unlike pre-announced audits, surprise visits capture routine manufacturing behavior, including batch handling, deviation responses, data controls, and investigation practices as they operate day-to-day.

Indian manufacturers that have strengthened quality governance, hired experts into compliance leadership, and standardized systems across global operations seem to be better positioned under surprise inspections. These changes reduce the probability that inspectors will find systemic, enforcement-level failures that trigger OAIs, even when inspections are unannounced.

According to Joseph Ryan Lambert, Vice President of Global Corporate Quality Assurance at Biocon and a former USFDA field inspector, the outcome reflects structural changes inside Indian drug plants rather than a softer regulatory approach. "Unannounced inspections don't change the standards—they change what inspectors actually see," he said. "If quality systems are working every day, not just on inspection days, facilities tend to hold up even when there's no advance notice."

| Year | Number of Inspections | Number of OAI Findings | | --- | --- | --- | | 2024 | 284 | 7 | | 2025 | 212 | 3 |

Lambert noted that enforcement outcomes increasingly hinge on whether companies maintain consistent investigation discipline. "The most common and serious issue I saw—worldwide, not just in India—was failing to extend investigations," he said. When something goes wrong, the expectation is that firms assess whether batches already on the market could be affected. That's a key FDA focus area, and where inspections often escalate.

Indian manufacturers that have adopted a single, global quality framework are better positioned under surprise inspections. "We don't operate different quality systems for different geographies," Lambert said. "There's one quality standard, one oversight model, regardless of whether a product is shipped to the US or anywhere else. That consistency reduces regulatory risk."

At the same time, the USFDA's enforcement mix has evolved. While OAIs have declined, Voluntary Action Indicated (VAI) outcomes have risen, suggesting inspectors are still identifying deficiencies but judging them to be correctable without formal enforcement. This reflects a regulatory preference to reserve OAIs for cases involving data integrity breakdowns, unresolved investigation failures, or risks to marketed product—rather than procedural gaps that firms can plausibly remediate.

Capacity constraints at the USFDA may also be a contributing factor. Workforce reductions and internal restructuring in early 2025 strained inspection resources, particularly for foreign sites. While the agency has reaffirmed its commitment to surprise inspections, fewer inspectors mean greater reliance on risk-based prioritisation. In such a framework, facilities with stable compliance histories are less likely to face repeat or escalation-level scrutiny, limiting the pool of sites that could generate OAIs.

Crucially, the drop in OAIs does not signal reduced regulatory pressure. Unannounced inspections raise the baseline expectation for continuous compliance and narrow the margin for error.